Thinking about what could have persuaded Illiad Research to value POTN above .45/share during Q1... It wasn't Q1 revs and certainly not earnings, nor the possibility of SEC reporting or uplisting since both were too far into the future and high risk several months ago. My best guess is that POTN has inked a distribution deal with a national pharmacy chain like CVS - and their edible CBD products will be available as soon as the FDA clarifies their rulings.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.